About biocardia inc - BCDA
BioCardia, Inc. is a clinical-stage biotherapeutic company, which engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its pipeline includes CardiAMP, CardiALLO, PulmALLO, Helix Biotherapeutic Delivery System, and Morph DNA and AVANCE Steerable Introducers. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.
BCDA At a Glance
BioCardia, Inc.
320 Soquel Way
Sunnyvale, California 94085
| Phone | 1-650-226-0120 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -8,228,000.00 | |
| Sector | Health Technology | Employees | 17 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
BCDA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 15.022 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.819 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.083 |
BCDA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -484,000.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
BCDA Liquidity
| Current Ratio | 1.123 |
| Quick Ratio | 1.123 |
| Cash Ratio | 1.026 |
BCDA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -230.573 |
| Return on Equity | -950.115 |
| Return on Total Capital | -578.215 |
| Return on Invested Capital | -690.268 |
BCDA Capital Structure
| Total Debt to Total Equity | 58.994 |
| Total Debt to Total Capital | 37.105 |
| Total Debt to Total Assets | 15.47 |
| Long-Term Debt to Equity | 9.609 |
| Long-Term Debt to Total Capital | 6.044 |